{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:29:35Z","timestamp":1791584975591,"version":"4.3.4"},"reference-count":129,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016242","name":"Boston Scientific","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In most patients with atrial fibrillation (AF), effective stroke prevention necessitates long-term (often lifelong) oral anticoagulant therapy (OAC). However, the effectiveness of OAC therapy in a clinical setting (i.e. outside the controlled environment of randomized clinical trials) is strongly influenced by patients\u2019 adherence and persistence with prescribed therapy. However, suboptimal adherence to OAC remains a substantial problem in routine practice\u2014available evidence suggests that patients do not take their OAC one out of every four days, and approximately one in three to four patients is poorly adherent to OAC. In addition, around 15% of high-risk OAC-eligible patients with AF refuse to take OAC for a variety of patient-specific reasons. Poor adherence to OAC therapy is associated with adverse clinical outcomes [such as stroke or systemic embolism, hospitalization, mortality, bleeding (particularly with vitamin K antagonist therapy)] and increased economic costs. In this overview, we summarize important aspects of the adherence to medication concept, including the definition and measurement of adherence, the determinants and prevalence of OAC non-adherence, the clinical importance of achieving and maintaining good adherence, strategies to improve adherence to OAC, and alternative treatment options for effective thromboprophylaxis in patients with AF who are non-adherent to OAC therapy.<\/jats:p>","DOI":"10.1093\/europace\/euaf250","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:59:36Z","timestamp":1760097576000},"source":"Crossref","is-referenced-by-count":23,"title":["Adherence to oral thromboprophylaxis in atrial fibrillation: an overview for clinicians"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6285-6902","authenticated-orcid":false,"given":"Tatjana","family":"Potpara","sequence":"first","affiliation":[{"name":"Medical Faculty, University of Belgrade , Dr Subotica starijeg 8, Belgrade 11000 ,","place":["Serbia"]},{"name":"Cardiology Clinic, University Clinical Centre of Serbia , Dr Subotica starijeg 13, Belgrade 11000 ,","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2216-0843","authenticated-orcid":false,"given":"Bogdan G","family":"Markovic","sequence":"additional","affiliation":[{"name":"Medical Faculty, University of Belgrade , Dr Subotica starijeg 8, Belgrade 11000 ,","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1134-7099","authenticated-orcid":false,"given":"Marek","family":"Grygier","sequence":"additional","affiliation":[{"name":"1st Department of Cardiology, Poznan University School of Medical Sciences , Poznan ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4699-4149","authenticated-orcid":false,"given":"Simonetta","family":"Genovesi","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, University of Milano-Bicocca, Nephrology Clinic , Monza ,","place":["Italy"]},{"name":"Istituto Auxologico Italiano, IRCCS , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6968-2191","authenticated-orcid":false,"given":"Apostolos","family":"Tzikas","sequence":"additional","affiliation":[{"name":"Ippokrateio Hospital of Thessaloniki, Aristotle University of Thessaloniki , Thessaloniki ,","place":["Greece"]},{"name":"Structural and Congenital Heart Disease, European Interbalkan Medical Centre , Thessaloniki ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1280-7042","authenticated-orcid":false,"given":"Serge","family":"Boveda","sequence":"additional","affiliation":[{"name":"Cardiology, Heart Rhythm Management Department, Clinique Pasteur , Toulouse ,","place":["France"]},{"name":"Cardiologie Clinique Pasteur, Brussels University VUB , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6473-2900","authenticated-orcid":false,"given":"Jens Erik","family":"Nielsen-Kudsk","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-4815","authenticated-orcid":false,"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[{"name":"Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena , Modena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital , Liverpool ,","place":["UK"]},{"name":"Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University , Aalborg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-2871","authenticated-orcid":false,"given":"A John","family":"Camm","sequence":"additional","affiliation":[{"name":"Genetic and Cardiovascular Sciences Institute, Cardiology Academic Group, St. George\u2019s University of London, Cranmer Terrace , London SW19 0RE ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"2025110105063154400_euaf250-B1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"2025110105063154400_euaf250-B2","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2025110105063154400_euaf250-B3","doi-asserted-by":"crossref","first-page":"e005969","DOI":"10.1161\/CIRCOUTCOMES.119.005969","article-title":"Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"13","author":"Ozaki","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2025110105063154400_euaf250-B4","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"2025110105063154400_euaf250-B5","doi-asserted-by":"crossref","first-page":"e034778","DOI":"10.1136\/bmjopen-2019-034778","article-title":"Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies","volume":"10","author":"Salmasi","year":"2020","journal-title":"BMJ Open"},{"key":"2025110105063154400_euaf250-B6","doi-asserted-by":"crossref","first-page":"A42","DOI":"10.1093\/eurheartj\/suab152","article-title":"Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation","volume":"24","author":"Farinha","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"2025110105063154400_euaf250-B7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"2025110105063154400_euaf250-B8","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jac5.1771","article-title":"Research and scholarly methods: measuring medication adherence","volume":"6","author":"Shah","year":"2023","journal-title":"J Am Coll Clin Pharm"},{"key":"2025110105063154400_euaf250-B9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4065\/mcp.2010.0575","article-title":"Medication adherence: WHO cares?","volume":"86","author":"Brown","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"2025110105063154400_euaf250-B10","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00392-023-02230-3","article-title":"Not obtaining a medication the first time it is prescribed: primary non-adherence to cardiovascular pharmacotherapy","volume":"113","author":"Schulz","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"2025110105063154400_euaf250-B11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4733.2006.00139.x","article-title":"A checklist for medication compliance and persistence studies using retrospective databases","volume":"10","author":"Peterson","year":"2007","journal-title":"Value Health"},{"key":"2025110105063154400_euaf250-B12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jval.2018.08.006","article-title":"Methods for measuring multiple medication adherence: a systematic review-report of the ISPOR medication adherence and persistence special interest group","volume":"22","author":"Pednekar","year":"2019","journal-title":"Value Health"},{"key":"2025110105063154400_euaf250-B13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1345\/aph.1K671","article-title":"Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication","volume":"43","author":"Martin","year":"2009","journal-title":"Ann Pharmacother"},{"key":"2025110105063154400_euaf250-B14","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2147\/PPA.S136890","article-title":"An upper and lower bound of the Medication Possession Ratio","volume":"11","author":"Sperber","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"2025110105063154400_euaf250-B15","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1345\/aph.1H018","article-title":"Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures","volume":"40","author":"Hess","year":"2006","journal-title":"Ann Pharmacother"},{"key":"2025110105063154400_euaf250-B16","first-page":"457","article-title":"Measuring concurrent adherence to multiple related medications","volume":"15","author":"Choudhry","year":"2009","journal-title":"Am J Manag Care"},{"key":"2025110105063154400_euaf250-B17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/MLR.0b013e3182984c1f","article-title":"Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence","volume":"51","author":"Franklin","year":"2013","journal-title":"Med Care"},{"key":"2025110105063154400_euaf250-B18","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/cpt.865","article-title":"Group-based trajectory models: assessing adherence to antihypertensive medication in older adults in a community pharmacy setting","volume":"103","author":"Dillon","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2025110105063154400_euaf250-B19","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0149-2918(99)80026-5","article-title":"Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice","volume":"21","author":"Farmer","year":"1999","journal-title":"Clin Ther"},{"key":"2025110105063154400_euaf250-B20","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jpeds.2011.05.018","article-title":"Electronic measurement of medication adherence in pediatric chronic illness: a review of measures","volume":"159","author":"Ingerski","year":"2011","journal-title":"J Pediatr"},{"key":"2025110105063154400_euaf250-B21","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s13142-015-0315-2","article-title":"Self-report measures of medication adherence behavior: recommendations on optimal use","volume":"5","author":"Stirratt","year":"2015","journal-title":"Transl Behav Med"},{"key":"2025110105063154400_euaf250-B22","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1177\/1078155218759184","article-title":"Using a treatment diary to improve the medication adherence in patients with chronic myeloid leukaemia","volume":"25","author":"Santoleri","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"2025110105063154400_euaf250-B23","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1007\/s10461-016-1406-x","article-title":"Validation of a new three-item self-report measure for medication adherence","volume":"20","author":"Wilson","year":"2016","journal-title":"AIDS Behav"},{"key":"2025110105063154400_euaf250-B24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1524-4733.2008.00400.x","article-title":"Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease","volume":"12","author":"Kripalani","year":"2009","journal-title":"Value Health"},{"key":"2025110105063154400_euaf250-B25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1185\/03007990802619425","article-title":"The Adherence Estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease","volume":"25","author":"McHorney","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"2025110105063154400_euaf250-B26","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/bcp.14193","article-title":"The Medication Adherence Report Scale: a measurement tool for eliciting patients\u2019 reports of nonadherence","volume":"86","author":"Chan","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2025110105063154400_euaf250-B27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10865-008-9170-7","article-title":"Revision and validation of the medication adherence self-efficacy scale (MASES) in hypertensive African Americans","volume":"31","author":"Fernandez","year":"2008","journal-title":"J Behav Med"},{"key":"2025110105063154400_euaf250-B28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0920-9964(99)00130-9","article-title":"Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses","volume":"42","author":"Thompson","year":"2000","journal-title":"Schizophr Res"},{"key":"2025110105063154400_euaf250-B29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0738-3991(98)00107-4","article-title":"The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence","volume":"37","author":"Svarstad","year":"1999","journal-title":"Patient Educ Couns"},{"key":"2025110105063154400_euaf250-B30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00002030-200203080-00012","article-title":"Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA study","volume":"16","author":"Knobel","year":"2002","journal-title":"AIDS"},{"key":"2025110105063154400_euaf250-B31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"key":"2025110105063154400_euaf250-B32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","article-title":"Predictive validity of a medication adherence measure in an outpatient setting","volume":"10","author":"Morisky","year":"2008","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2025110105063154400_euaf250-B33","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/hematology.2024000666","article-title":"DOACs: role of anti-Xa and drug level monitoring","volume":"2024","author":"Mithoowani","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2025110105063154400_euaf250-B34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1345\/aph.1D252","article-title":"Measurement, correlates, and health outcomes of medication adherence among seniors","volume":"38","author":"Vik","year":"2004","journal-title":"Ann Pharmacother"},{"key":"2025110105063154400_euaf250-B35","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/jamia\/ocv054","article-title":"An algorithm to identify medication nonpersistence using electronic pharmacy databases","volume":"22","author":"Parker","year":"2015","journal-title":"J Am Med Inform Assoc"},{"key":"2025110105063154400_euaf250-B36","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1016\/j.sapharm.2021.03.016","article-title":"Primary medication nonadherence calculation method specifications impact resulting rates","volume":"18","author":"Zuckerman","year":"2022","journal-title":"Res Social Adm Pharm"},{"key":"2025110105063154400_euaf250-B37","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11606-010-1253-9","article-title":"Primary medication non-adherence: analysis of 195,930 electronic prescriptions","volume":"25","author":"Fischer","year":"2010","journal-title":"J Gen Intern Med"},{"key":"2025110105063154400_euaf250-B38","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2147\/PPA.S161151","article-title":"Primary nonadherence to chronic disease medications: a meta-analysis","volume":"12","author":"Lemstra","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"2025110105063154400_euaf250-B39","doi-asserted-by":"crossref","first-page":"e13350","DOI":"10.1111\/ijcp.13350","article-title":"Prevalence of and factors associated with primary medication non-adherence in chronic disease: a systematic review and meta-analysis","volume":"73","author":"Cheen","year":"2019","journal-title":"Int J Clin Pract"},{"key":"2025110105063154400_euaf250-B40","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/bcp.13215","article-title":"Initial medication non-adherence: prevalence and predictive factors in a cohort of 1.6 million primary care patients","volume":"83","author":"Aznar-Lou","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2025110105063154400_euaf250-B41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/bcp.15472","article-title":"Primary nonadherence to drugs prescribed by general practitioners: a Dutch database study","volume":"89","author":"Hempenius","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"2025110105063154400_euaf250-B42","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00228-014-1677-y","article-title":"Primary non-adherence in general practice: a Danish register study","volume":"70","author":"Pottegard","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"2025110105063154400_euaf250-B43","first-page":"440","article-title":"Primary nonadherence to oral anticoagulants in patients with atrial fibrillation: real-world data from a population-based cohort","volume":"24","author":"Rodriguez-Bernal","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"2025110105063154400_euaf250-B44","first-page":"1210","article-title":"Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation","volume":"27","author":"Charlton","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"2025110105063154400_euaf250-B45","first-page":"8","article-title":"Primary nonadherence to medication and its drivers in Poland: findings from the electronic prescription pilot analysis","volume":"130","author":"Kardas","year":"2020","journal-title":"Pol Arch Intern Med"},{"key":"2025110105063154400_euaf250-B46","first-page":"778","article-title":"Reasons for primary medication nonadherence: a systematic review and metric analysis","volume":"24","author":"Lee","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"2025110105063154400_euaf250-B47","doi-asserted-by":"crossref","first-page":"441","DOI":"10.7326\/M13-1705","article-title":"The incidence and determinants of primary nonadherence with prescribed medication in primary care: a cohort study","volume":"160","author":"Tamblyn","year":"2014","journal-title":"Ann Intern Med"},{"key":"2025110105063154400_euaf250-B48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjopharm.2011.02.004","article-title":"A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity","volume":"9","author":"Gellad","year":"2011","journal-title":"Am J Geriatr Pharmacother"},{"key":"2025110105063154400_euaf250-B49","doi-asserted-by":"crossref","first-page":"520","DOI":"10.46747\/cfp.6807520","article-title":"Primary medication nonadherence in a large primary care population: observational study from Manitoba","volume":"68","author":"Singer","year":"2022","journal-title":"Can Fam Physician"},{"key":"2025110105063154400_euaf250-B50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/02813432.2015.1132884","article-title":"Primary adherence to antidepressant prescriptions in primary health care: a population-based study in Sweden","volume":"34","author":"Freccero","year":"2016","journal-title":"Scand J Prim Health Care"},{"key":"2025110105063154400_euaf250-B51","doi-asserted-by":"crossref","first-page":"e61735","DOI":"10.1371\/journal.pone.0061735","article-title":"Primary medication non-adherence after discharge from a general internal medicine service","volume":"8","author":"Fallis","year":"2013","journal-title":"PLoS One"},{"key":"2025110105063154400_euaf250-B52","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jamadermatol.2016.3491","article-title":"Association between method of prescribing and primary nonadherence to dermatologic medication in an urban hospital population","volume":"153","author":"Adamson","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2025110105063154400_euaf250-B53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cardfail.2013.11.006","article-title":"Adherence and persistence in the use of warfarin after hospital discharge among patients with heart failure and atrial fibrillation","volume":"20","author":"Eapen","year":"2014","journal-title":"J Card Fail"},{"key":"2025110105063154400_euaf250-B54","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.1230","article-title":"Methods for evaluation of medication adherence and persistence using automated databases","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025110105063154400_euaf250-B55","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3389\/fphar.2018.01290","article-title":"A systematic review of medication adherence thresholds dependent of clinical outcomes","volume":"9","author":"Baumgartner","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025110105063154400_euaf250-B56","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12872-017-0671-6","article-title":"Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration","volume":"17","author":"Borne","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"2025110105063154400_euaf250-B57","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/phar.1989","article-title":"Real-world adherence and persistence with direct oral anticoagulants in adults with atrial fibrillation","volume":"37","author":"Manzoor","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2025110105063154400_euaf250-B58","doi-asserted-by":"crossref","first-page":"e0194099","DOI":"10.1371\/journal.pone.0194099","article-title":"Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: analysis of overall population and subgroups of prior oral anticoagulant users","volume":"13","author":"McHorney","year":"2018","journal-title":"PLoS One"},{"key":"2025110105063154400_euaf250-B59","doi-asserted-by":"crossref","first-page":"e021601","DOI":"10.1161\/JAHA.121.021601","article-title":"Long-term medication adherence trajectories to direct oral anticoagulants and clinical outcomes in patients with atrial fibrillation","volume":"10","author":"An","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025110105063154400_euaf250-B60","first-page":"101","article-title":"Pharmacy-led management of atrial fibrillation: improving treatment adherence and patient outcomes","volume":"13","author":"Veale","year":"2024","journal-title":"Integr Pharm Res Pract"},{"key":"2025110105063154400_euaf250-B61","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/jth.12845","article-title":"Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study","volume":"13","author":"Gorst-Rasmussen","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2025110105063154400_euaf250-B62","doi-asserted-by":"crossref","first-page":"e020212","DOI":"10.1136\/bmjopen-2017-020212","article-title":"Dabigatran persistence and adherence in New Zealand: a nationwide retrospective observational study","volume":"8","author":"Harper","year":"2018","journal-title":"BMJ Open"},{"key":"2025110105063154400_euaf250-B63","doi-asserted-by":"crossref","first-page":"e016980","DOI":"10.1136\/bmjopen-2017-016980","article-title":"Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada","volume":"8","author":"McAlister","year":"2018","journal-title":"BMJ Open"},{"key":"2025110105063154400_euaf250-B64","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/pds.4268","article-title":"Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study","volume":"26","author":"Maura","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025110105063154400_euaf250-B65","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s41999-023-00811-z","article-title":"Anticoagulant use in older persons at risk for falls: therapeutic dilemmas-a clinical review","volume":"14","author":"Mitchell","year":"2023","journal-title":"Eur Geriatr Med"},{"key":"2025110105063154400_euaf250-B66","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s11239-019-01898-7","article-title":"Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls","volume":"48","author":"Miao","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"2025110105063154400_euaf250-B67","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/archinte.159.7.677","article-title":"Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls","volume":"159","author":"Man-Son-Hing","year":"1999","journal-title":"Arch Intern Med"},{"key":"2025110105063154400_euaf250-B68","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2025110105063154400_euaf250-B69","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1111\/jth.15415","article-title":"Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: results from the GARFIELD-AF registry","volume":"19","author":"Cools","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2025110105063154400_euaf250-B70","doi-asserted-by":"crossref","first-page":"e239638","DOI":"10.1001\/jamanetworkopen.2023.9638","article-title":"Patients and their physician's perspectives about oral anticoagulation in patients with atrial fibrillation not receiving an anticoagulant","volume":"6","author":"Cannon","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025110105063154400_euaf250-B71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijcard.2016.03.212","article-title":"Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke","volume":"215","author":"Alberts","year":"2016","journal-title":"Int J Cardiol"},{"key":"2025110105063154400_euaf250-B72","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/03007995.2018.1428543","article-title":"Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants","volume":"34","author":"Deshpande","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"2025110105063154400_euaf250-B73","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ahj.2014.03.023","article-title":"Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration","volume":"167","author":"Shore","year":"2014","journal-title":"Am Heart J"},{"key":"2025110105063154400_euaf250-B74","first-page":"302","article-title":"The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective","volume":"19","author":"Casciano","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"2025110105063154400_euaf250-B75","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00228-015-1983-z","article-title":"Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation","volume":"72","author":"Forslund","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"2025110105063154400_euaf250-B76","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/heartjnl-2016-310672","article-title":"Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation","volume":"103","author":"Jackevicius","year":"2017","journal-title":"Heart"},{"key":"2025110105063154400_euaf250-B77","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/00325481.2015.1074032","article-title":"Discontinuation of oral anticoagulation preceding acute ischemic stroke\u2013prevalence and outcomes: comprehensive chart review","volume":"127","author":"Vanga","year":"2015","journal-title":"Postgrad Med"},{"key":"2025110105063154400_euaf250-B78","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10557-023-07507-3","article-title":"Minimal adherence threshold to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation to reduce the risk of thromboembolism and death: a nationwide cohort study","volume":"39","author":"Grymonprez","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"2025110105063154400_euaf250-B79","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.2147\/PPA.S324315","article-title":"Estimated thresholds of minimum necessary adherence for effective treatment with direct oral anticoagulants\u2014a retrospective cohort study in health insurance claims data","volume":"15","author":"Wirbka","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"2025110105063154400_euaf250-B80","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10840-018-0465-5","article-title":"Shared decision-making in atrial fibrillation: navigating complex issues in partnership with the patient","volume":"56","author":"Noseworthy","year":"2019","journal-title":"J Interv Card Electrophysiol"},{"key":"2025110105063154400_euaf250-B81","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/europace\/euv025","article-title":"How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe? Results of the European Heart Rhythm Association Survey","volume":"17","author":"Potpara","year":"2015","journal-title":"Europace"},{"key":"2025110105063154400_euaf250-B82","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1093\/europace\/euaa210","article-title":"Self-reported treatment burden in patients with atrial fibrillation: quantification, major determinants, and implications for integrated holistic management of the arrhythmia","volume":"22","author":"Potpara","year":"2020","journal-title":"Europace"},{"key":"2025110105063154400_euaf250-B83","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1160\/TH16-10-0787","article-title":"Patient values and preferences for antithrombotic therapy in atrial fibrillation. A narrative systematic review","volume":"117","author":"Loewen","year":"2017","journal-title":"Thromb Haemost"},{"key":"2025110105063154400_euaf250-B84","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ijcard.2016.08.303","article-title":"Knowledge gaps in patients with atrial fibrillation revealed by a new validated knowledge questionnaire","volume":"223","author":"Desteghe","year":"2016","journal-title":"Int J Cardiol"},{"key":"2025110105063154400_euaf250-B85","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40271-016-0185-9","article-title":"Patient preferences for oral anticoagulation therapy in atrial fibrillation: a systematic literature review","volume":"10","author":"Wilke","year":"2017","journal-title":"Patient"},{"key":"2025110105063154400_euaf250-B86","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/eurjcn\/zvad094","article-title":"Patient concern regarding bleeding side effects from oral anticoagulation therapy for atrial fibrillation: an analysis from the multicentre KiCS-AF registry","volume":"23","author":"Ueda","year":"2024","journal-title":"Eur J Cardiovasc Nurs"},{"key":"2025110105063154400_euaf250-B87","first-page":"CD008600","article-title":"Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation","volume":"4","author":"Clarkesmith","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025110105063154400_euaf250-B88","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(17)32165-7","article-title":"A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial","volume":"390","author":"Vinereanu","year":"2017","journal-title":"Lancet"},{"key":"2025110105063154400_euaf250-B89","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40256-019-00356-2","article-title":"Educational impact on apixaban adherence in atrial fibrillation (the AEGEAN STUDY): a randomized clinical trial","volume":"20","author":"Montalescot","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"2025110105063154400_euaf250-B90","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/1474515118804353","article-title":"Effect of reinforced, targeted in-person education using the Jessa Atrial fibrillation Knowledge Questionnaire in patients with atrial fibrillation: a randomized controlled trial","volume":"18","author":"Desteghe","year":"2019","journal-title":"Eur J Cardiovasc Nurs"},{"key":"2025110105063154400_euaf250-B91","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1007\/s00392-023-02261-w","article-title":"Adherence to oral anticoagulation measured by electronic monitoring in a Belgian atrial fibrillation population","volume":"112","author":"Knaepen","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2025110105063154400_euaf250-B92","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1182\/bloodadvances.2019000067","article-title":"A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation","volume":"3","author":"Paquette","year":"2019","journal-title":"Blood Adv"},{"key":"2025110105063154400_euaf250-B93","doi-asserted-by":"crossref","first-page":"f63","DOI":"10.1093\/ehjcvp\/pvaa039","article-title":"Motivational Interviewing to Support Oral AntiCoagulation adherence in patients with non-valvular Atrial Fibrillation (MISOAC-AF): a randomized clinical trial","volume":"7","author":"Tzikas","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025110105063154400_euaf250-B94","doi-asserted-by":"crossref","first-page":"euae211","DOI":"10.1093\/europace\/euae211","article-title":"Effect of targeted education of patients with atrial fibrillation on unplanned cardiovascular outcomes: results of the multicentre randomized AF-EduCare trial","volume":"27","author":"Desteghe","year":"2025","journal-title":"Europace"},{"key":"2025110105063154400_euaf250-B95","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/eurheartj\/ehx807","article-title":"Innovative strategies to improve adherence to non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation","volume":"39","author":"Lip","year":"2018","journal-title":"Eur Heart J"},{"key":"2025110105063154400_euaf250-B96","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euaa269","article-title":"Mobile health applications for managing atrial fibrillation for healthcare professionals and patients: a systematic review","author":"Lane","year":"2020","journal-title":"Europace"},{"key":"2025110105063154400_euaf250-B97","doi-asserted-by":"crossref","first-page":"e032045","DOI":"10.1136\/bmjopen-2019-032045","article-title":"Do mobile device apps designed to support medication adherence demonstrate efficacy? A systematic review of randomised controlled trials, with meta-analysis","volume":"10","author":"Armitage","year":"2020","journal-title":"BMJ Open"},{"key":"2025110105063154400_euaf250-B98","doi-asserted-by":"crossref","first-page":"e24190","DOI":"10.2196\/24190","article-title":"Mobile apps to improve medication adherence in cardiovascular disease: systematic review and meta-analysis","volume":"23","author":"Al-Arkee","year":"2021","journal-title":"J Med Internet Res"},{"key":"2025110105063154400_euaf250-B99","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1055\/s-0043-1769612","article-title":"Mobile health-technology-integrated care for atrial fibrillation: a win ratio analysis from the mAFA-II randomized clinical trial","volume":"123","author":"Romiti","year":"2023","journal-title":"Thromb Haemost"},{"key":"2025110105063154400_euaf250-B100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejim.2020.09.024","article-title":"Mobile health technology-supported atrial fibrillation screening and integrated care: a report from the mAFA-II trial Long-term Extension Cohort","volume":"82","author":"Guo","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2025110105063154400_euaf250-B101","doi-asserted-by":"crossref","first-page":"e65010","DOI":"10.2196\/65010","article-title":"Smartphone app for improving self-awareness of adherence to edoxaban treatment in patients with atrial fibrillation (ADHERE-app trial): randomized controlled trial","volume":"26","author":"Yoon","year":"2024","journal-title":"J Med Internet Res"},{"key":"2025110105063154400_euaf250-B102","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1161\/CIRCOUTCOMES.115.002366","article-title":"Reimagining anticoagulation clinics in the era of direct oral anticoagulants","volume":"9","author":"Barnes","year":"2016","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2025110105063154400_euaf250-B103","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1093\/eurheartj\/ehs071","article-title":"Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation","volume":"33","author":"Hendriks","year":"2012","journal-title":"Eur Heart J"},{"key":"2025110105063154400_euaf250-B104","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/eurheartj\/ehz666","article-title":"Nurse-led vs. usual-care for atrial fibrillation","volume":"41","author":"Wijtvliet","year":"2020","journal-title":"Eur Heart J"},{"key":"2025110105063154400_euaf250-B105","doi-asserted-by":"crossref","first-page":"e013236","DOI":"10.1161\/CIRCEP.124.013236","article-title":"Nurse-led multicomponent behavioral activation intervention for patients with atrial fibrillation: a randomized controlled trial","volume":"18","author":"Li","year":"2025","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2025110105063154400_euaf250-B106","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.hroo.2024.04.005","article-title":"A targeted educational intervention increases oral anticoagulation rates in high-risk atrial fibrillation patients","volume":"5","author":"Dutta","year":"2024","journal-title":"Heart Rhythm O2"},{"key":"2025110105063154400_euaf250-B107","doi-asserted-by":"crossref","first-page":"e006418","DOI":"10.1161\/CIRCOUTCOMES.120.006418","article-title":"Multimodal interventions to increase anticoagulant utilization in atrial fibrillation: futile without patient engagement?","volume":"13","author":"Siontis","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2025110105063154400_euaf250-B108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12959-024-00614-7","article-title":"Clinical decision support systems to optimize adherence to anticoagulant guidelines in patients with atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Amin","year":"2024","journal-title":"Thromb J"},{"key":"2025110105063154400_euaf250-B109","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.thromres.2019.12.023","article-title":"Do computerized clinical decision support systems improve the prescribing of oral anticoagulants? A systematic review","volume":"187","author":"Sennesael","year":"2020","journal-title":"Thromb Res"},{"key":"2025110105063154400_euaf250-B110","doi-asserted-by":"crossref","first-page":"e0193187","DOI":"10.1371\/journal.pone.0193187","article-title":"Acceptance and barriers pertaining to a general practice decision support system for multiple clinical conditions: a mixed methods evaluation","volume":"13","author":"Arts","year":"2018","journal-title":"PLoS One"},{"key":"2025110105063154400_euaf250-B111","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/CIRCULATIONAHA.109.884031","article-title":"Computerized decision support for the cardiovascular clinician: applications for venous thromboembolism prevention and beyond","volume":"120","author":"Piazza","year":"2009","journal-title":"Circulation"},{"key":"2025110105063154400_euaf250-B112","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jamainternmed.2020.2908","article-title":"Assessment of shared decision-making for stroke prevention in patients with atrial fibrillation: a randomized clinical trial","volume":"180","author":"Kunneman","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2025110105063154400_euaf250-B113","doi-asserted-by":"crossref","first-page":"e023048","DOI":"10.1161\/JAHA.121.023048","article-title":"Effect of shared decision-making for stroke prevention on treatment adherence and safety outcomes in patients with atrial fibrillation: a randomized clinical trial","volume":"11","author":"Noseworthy","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2025110105063154400_euaf250-B114","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1185\/03007995.2012.677419","article-title":"Effect of dosing frequency on chronic cardiovascular disease medication adherence","volume":"28","author":"Coleman","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"2025110105063154400_euaf250-B115","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2016.04.082","article-title":"Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: a meta-regression analysis","volume":"216","author":"Weeda","year":"2016","journal-title":"Int J Cardiol"},{"key":"2025110105063154400_euaf250-B116","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40119-023-00315-8","article-title":"Anticoagulant treatment adherence and persistence in German patients with atrial fibrillation","volume":"12","author":"Patti","year":"2023","journal-title":"Cardiol Ther"},{"key":"2025110105063154400_euaf250-B117","first-page":"980","article-title":"Adherence to rivaroxaban compared with other oral anticoagulant agents among patients with nonvalvular atrial fibrillation","volume":"23","author":"McHorney","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"2025110105063154400_euaf250-B118","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1161\/CIRCULATIONAHA.108.768986","article-title":"Medication adherence: its importance in cardiovascular outcomes","volume":"119","author":"Ho","year":"2009","journal-title":"Circulation"},{"key":"2025110105063154400_euaf250-B119","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1182\/bloodadvances.2024013854","article-title":"Handling delayed or missed direct oral anticoagulant doses: model-informed individual remedial dosing","volume":"8","author":"Liu","year":"2024","journal-title":"Blood Adv"},{"key":"2025110105063154400_euaf250-B120","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jacc.2022.11.057","article-title":"Clinical evaluation of factor XIa inhibitor drugs: JACC Review Topic of the Week","volume":"81","author":"Harrington","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025110105063154400_euaf250-B121","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1055\/s-0040-1710013","article-title":"Role of factor XIa and plasma kallikrein in arterial and venous thrombosis","volume":"120","author":"Visser","year":"2020","journal-title":"Thromb Haemost"},{"key":"2025110105063154400_euaf250-B122","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"2025110105063154400_euaf250-B123","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"2025110105063154400_euaf250-B124","doi-asserted-by":"crossref","first-page":"euae035","DOI":"10.1093\/europace\/euae035","article-title":"Practical guide on left atrial appendage closure for the non-implanting physician: an international consensus paper","volume":"26","author":"Potpara","year":"2024","journal-title":"Europace"},{"key":"2025110105063154400_euaf250-B125","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1016\/j.jacc.2020.08.089","article-title":"Left atrial appendage closure versus oral anticoagulants in atrial fibrillation: a meta-analysis of randomized trials","volume":"76","author":"Turagam","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025110105063154400_euaf250-B126","first-page":"2914","article-title":"Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives","volume":"45","author":"Landmesser","year":"2024","journal-title":"Eur Heart J"},{"key":"2025110105063154400_euaf250-B127","doi-asserted-by":"crossref","first-page":"e034815","DOI":"10.1161\/JAHA.124.034815","article-title":"Left atrial appendage closure compared with oral anticoagulants for patients with atrial fibrillation: a systematic review and network meta-analysis","volume":"13","author":"Oliva","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2025110105063154400_euaf250-B128","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/s41598-021-82359-1","article-title":"Preclinical assessment of a modified Occlutech left atrial appendage closure device in a porcine model","volume":"11","author":"Reinthaler","year":"2021","journal-title":"Sci Rep"},{"key":"2025110105063154400_euaf250-B129","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2022.02.047","article-title":"Antithrombotic therapy after left atrial appendage occlusion in patients with atrial fibrillation","volume":"79","author":"Freeman","year":"2022","journal-title":"J Am Coll Cardiol"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/advance-article-pdf\/doi\/10.1093\/europace\/euaf250\/64661153\/euaf250.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/27\/11\/euaf250\/64661153\/euaf250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/27\/11\/euaf250\/64661153\/euaf250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:06:48Z","timestamp":1761988008000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euaf250\/8285104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":129,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,10,31]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euaf250","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,13]]},"article-number":"euaf250"}}